Stocks and Investing
Stocks and Investing
Fri, August 16, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salim Syed Upgraded (ATRA) to Buy and Decreased Target to $18 on, Aug 16th, 2024
Salim Syed of Mizuho, Upgraded "Atara Biotherapeutics, Inc." (ATRA) to Buy and Decreased Target from $25 to $18 on, Aug 16th, 2024.
Salim has made no other calls on ATRA in the last 4 months.
There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 1 agrees with Salim's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Robert Burns of "HC Wainwright & Co." Reiterated at Hold on, Wednesday, May 22nd, 2024
These are the ratings of the 2 analyists that currently disagree with Salim
- John Newman of "Canaccord Genuity" Maintained at Strong Buy and Held Target at $13 on, Tuesday, August 13th, 2024
- Tommie Reerink of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $11 on, Wednesday, July 17th, 2024
Contributing Sources